A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Chemotherapy Induced Anemia Clinical Trial

Official title:
A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Status Completed

Clinical Trial Summary

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Chemotherapy Induced Anemia

Clinical Trial Details

NCT number	NCT00144482
Study type	Interventional
Source	Chugai Pharmaceutical
Contact
Status	Completed
Phase	Phase 3
Start date	December 2003
Completion date	August 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05301517` - A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies	Phase 3
Terminated	`NCT00931606` - Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)	Phase 2
Completed	`NCT00272662` - Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy	Phase 2
Completed	`NCT00144495` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3
Not yet recruiting	`NCT06075030` - A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy	Phase 2
Completed	`NCT04076943` - Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia	Phase 2